Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30142989 | 1.00 | CHRNB2 (0.48) | CHRNB2CHRNA4NAPRTCYP1A2CYP2D6 | |
| Tetrahydrofuran SCHEMBL28632646 | 0.87 | ALDH1A1 (0.42) | CHRNB2CHRNA4NAPRTCYP1A2CYP2D6 | |
| SCHEMBL17168324 | 0.81 | CHRNA7 (0.52) | CHRNB2CHRNA4NAPRTCYP1A2CYP2D6 | |
| SCHEMBL1027113 | 0.81 | MIF (0.59) | CHRNB2CHRNA4NAPRTCYP1A2CYP2D6 | |
| Bromide SCHEMBL2337339 | 0.79 | MIF (0.57) | CHRNB2CHRNA4NAPRTCYP1A2CYP2D6 | |
| SCHEMBL3936550 | 0.79 | CYP1A2 (0.58) | CHRNB2CHRNA4NAPRTCYP1A2CYP2D6 | |
| SCHEMBL18500410 | 0.78 | — | — | |
| SCHEMBL11033045 | 0.75 | LOXL2 (0.41) | CYP1A2CYP2D6FDPSCYP3A4CYP2C9 | |
| SCHEMBL8193469 | 0.75 | NAAA (0.44) | CHRNB2CHRNA4NAPRTCYP1A2CYP2D6 | |
| SCHEMBL1172136 | 0.74 | MIF (0.60) | CYP2A6CYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117926640-A | Environment-friendly decorative paper and preparation method thereof | 浙江锦尚添彩新材料有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-117926640-B | Environment-friendly decorative paper and preparation method thereof | 浙江锦尚添彩新材料有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-117926640-A | Environment-friendly decorative paper and preparation method thereof | 浙江锦尚添彩新材料有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-111848506-B | Biphenyl urea compound and pharmaceutical composition, preparation method and application thereof | 中国药科大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-113717159-A | Indolone compounds and pharmaceutical composition, preparation method and application thereof | 中国药科大学 | 2021-11-30 | — | — | CN | disclosed |
| CN-111848506-A | Biphenyl urea compound and pharmaceutical composition, preparation method and application thereof | 中国药科大学 | 2020-10-30 | — | — | CN | disclosed |
| CN-108530444-A | A kind of novel NAMPT and IDO double inhibitors and preparation method thereof and medical usage | 中国药科大学 | 2018-09-14 | — | — | CN | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-5919811-A | NEURODEGENERATIVE DISORDERS | GLAXO WELLCOME S.P.A. (IT) | 1999-07-06 | — | — | US | disclosed |
| EP-0813524-A1 | INDOLE DERIVATIVES AS EAA ANTAGONISTS | GLAXO WELLCOME S.p.A. (IT) | 1997-12-29 | — | — | EP | disclosed |
| EP-0767800-A1 | HISTIDINE AND HOMOHISTIDINE DERIVATIVES AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |
| US-5571792-A | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase | WARNER-LAMBERT COMPANY (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1996027588-A1 | INDOLE DERIVATIVES AS EAA ANTAGONISTS | GLAXO WELLCOME S.P.A. (IT) | 1996-09-12 | — | — | WO | disclosed |
| WO-1996000736-A1 | HISTIDINE AND HOMOHISTIDINE DERIVATIVES AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1996-01-11 | — | — | WO | disclosed |
| EP-0004187-B1 | HETEROCYCLYLCARBONYL DERIVATIVES OF UREA AND THEIR USE AS AGENTS FOR DISSOLUTION OF GALLSTONES | PFIZER INC. (US) | 1982-03-17 | — | — | EP | disclosed |
| US-4252957-A | GALLSTONE SOLVENTS | PFIZER INC. (US) | 1981-02-24 | — | — | US | disclosed |
| EP-0004187-A1 | Heterocyclylcarbonyl derivatives of urea and their use as agents for dissolution of gallstones | PFIZER INC. (US) | 1979-09-19 | — | — | EP | disclosed |
| US-4163784-A | ACYLUREA DERIVATIVES | PFIZER INC. (US) | 1979-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CHRNB2 4251/4885CHRNA4 4756/4885NAPRT 1278/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CHRNB2 4251/4885CHRNA4 4756/4885NAPRT 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.